PL3826667T3 - Przeciwciała przeciwko klaudynie6 i sposoby leczenia nowotworu - Google Patents

Przeciwciała przeciwko klaudynie6 i sposoby leczenia nowotworu

Info

Publication number
PL3826667T3
PL3826667T3 PL18857242.4T PL18857242T PL3826667T3 PL 3826667 T3 PL3826667 T3 PL 3826667T3 PL 18857242 T PL18857242 T PL 18857242T PL 3826667 T3 PL3826667 T3 PL 3826667T3
Authority
PL
Poland
Prior art keywords
claudin6
antibodies
methods
treating cancer
cancer
Prior art date
Application number
PL18857242.4T
Other languages
English (en)
Polish (pl)
Inventor
Dylan CONKLIN
Dennis Slamon
Neil O'Brien
Mike PALAZZOLO
Erika VON EUW
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of PL3826667T3 publication Critical patent/PL3826667T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
PL18857242.4T 2017-09-18 2018-09-18 Przeciwciała przeciwko klaudynie6 i sposoby leczenia nowotworu PL3826667T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18
PCT/US2018/051610 WO2019056023A2 (en) 2017-09-18 2018-09-18 ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER

Publications (1)

Publication Number Publication Date
PL3826667T3 true PL3826667T3 (pl) 2024-09-30

Family

ID=65723110

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18857242.4T PL3826667T3 (pl) 2017-09-18 2018-09-18 Przeciwciała przeciwko klaudynie6 i sposoby leczenia nowotworu

Country Status (22)

Country Link
US (4) US20200291111A1 (cg-RX-API-DMAC7.html)
EP (2) EP4435009A3 (cg-RX-API-DMAC7.html)
JP (2) JP7599332B2 (cg-RX-API-DMAC7.html)
KR (2) KR102793719B1 (cg-RX-API-DMAC7.html)
CN (2) CN118667021A (cg-RX-API-DMAC7.html)
AU (2) AU2018334434B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020005196A2 (cg-RX-API-DMAC7.html)
CA (1) CA3076207A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2021138A3 (cg-RX-API-DMAC7.html)
DK (1) DK3826667T3 (cg-RX-API-DMAC7.html)
ES (1) ES2986343T3 (cg-RX-API-DMAC7.html)
FI (1) FI3826667T3 (cg-RX-API-DMAC7.html)
GB (1) GB202103867D0 (cg-RX-API-DMAC7.html)
HU (1) HUE067603T2 (cg-RX-API-DMAC7.html)
IL (2) IL273196B2 (cg-RX-API-DMAC7.html)
MX (2) MX2020002921A (cg-RX-API-DMAC7.html)
NO (1) NO20210351A1 (cg-RX-API-DMAC7.html)
PL (1) PL3826667T3 (cg-RX-API-DMAC7.html)
PT (1) PT3826667T (cg-RX-API-DMAC7.html)
SG (1) SG11202002114RA (cg-RX-API-DMAC7.html)
SI (1) SI3826667T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019056023A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002921A (es) * 2017-09-18 2020-09-28 Univ California Anticuerpos para claudin6 y métodos para tratar el cáncer.
IL273471B2 (en) 2017-09-29 2023-09-01 Daiichi Sankyo Co Ltd Conjugation of an antibody with a pyrrolobenzodiazepine derivative
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
SG11202108281UA (en) 2019-02-15 2021-08-30 Integral Molecular Inc Claudin 6 antibodies and uses thereof
JP7682797B2 (ja) * 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体
JP7682798B2 (ja) * 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６抗体及び薬物複合体
JP2023529557A (ja) 2020-05-04 2023-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗ｅｎｐｐ１抗体の阻害
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
US20250042996A1 (en) * 2021-11-16 2025-02-06 Christopher Bebbington Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
JP2025508362A (ja) * 2022-02-09 2025-03-26 セラ プログノスティックス， インコーポレイテッド Ｓｈｂｇおよびｉｂｐ４抗体、ならびにそれを使用する方法
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
WO2025075127A1 (ja) * 2023-10-04 2025-04-10 公立大学法人福島県立医科大学 がんのバイオマーカー及び抗体治療
WO2025146161A1 (en) * 2024-01-04 2025-07-10 Hansoh Bio Llc Antibody, antigen-binding fragment and medical use thereof
WO2025162270A1 (zh) * 2024-02-01 2025-08-07 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US6303144B1 (en) 1998-02-10 2001-10-16 Welfide Corporation Preparations with controlled release
JP2003530297A (ja) 1998-10-16 2003-10-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｖｉｐアンタゴニストを用いる併用療法
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
US7917208B2 (en) 2002-10-04 2011-03-29 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
JP5632582B2 (ja) * 2006-12-14 2014-11-26 中外製薬株式会社 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA
EP3064512B1 (en) * 2008-01-11 2023-08-30 The University of Tokyo Anti-cldn6 antibody
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
DK2707390T3 (en) * 2011-05-13 2016-02-29 Ganymed Pharmaceuticals Ag ANTIBODIES TO TREAT CANCER EXPRESSING CLAUDIN 6
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
BR112016010169A2 (pt) * 2013-11-06 2017-12-05 Stemcentrx Inc anticorpos anticlaudina e métodos de uso
CA2942459C (en) * 2014-04-01 2023-03-07 Biontech Cell & Gene Therapies Gmbh Claudin-6-specific immunoreceptors and t cell epitopes
MX2020002921A (es) * 2017-09-18 2020-09-28 Univ California Anticuerpos para claudin6 y métodos para tratar el cáncer.

Also Published As

Publication number Publication date
SG11202002114RA (en) 2020-04-29
WO2019056023A2 (en) 2019-03-21
KR102793719B1 (ko) 2025-04-08
BR112020005196A2 (pt) 2020-09-15
JP2024150445A (ja) 2024-10-23
AU2025200467A1 (en) 2025-04-10
IL313238A (en) 2024-07-01
GB202103867D0 (en) 2021-05-05
US20250333501A1 (en) 2025-10-30
IL273196B2 (en) 2024-11-01
SI3826667T1 (sl) 2024-09-30
CA3076207A1 (en) 2019-03-21
DK3826667T3 (da) 2024-07-22
MX2020002921A (es) 2020-09-28
PT3826667T (pt) 2024-08-02
MX2025012685A (es) 2025-11-03
US20200291111A1 (en) 2020-09-17
JP2020536507A (ja) 2020-12-17
FI3826667T3 (fi) 2024-07-22
ES2986343T3 (es) 2024-11-11
EP3826667A4 (en) 2022-07-27
EP3826667B1 (en) 2024-04-17
EP4435009A3 (en) 2025-02-26
NO20210351A1 (en) 2021-03-18
CN111565744B (zh) 2024-12-31
US20240400674A1 (en) 2024-12-05
AU2018334434B2 (en) 2025-01-23
KR20200070238A (ko) 2020-06-17
CN111565744A (zh) 2020-08-21
KR20250050137A (ko) 2025-04-14
EP3826667A2 (en) 2021-06-02
IL273196B1 (en) 2024-07-01
WO2019056023A3 (en) 2019-05-16
EP4435009A2 (en) 2024-09-25
CZ2021138A3 (cs) 2021-09-15
HUE067603T2 (hu) 2024-10-28
AU2018334434A1 (en) 2020-04-02
US20220372134A1 (en) 2022-11-24
IL273196A (en) 2020-04-30
CN118667021A (zh) 2024-09-20
JP7599332B2 (ja) 2024-12-13

Similar Documents

Publication Publication Date Title
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL275663A (en) Cancer treatment methods
IL289663A (en) Claudin 18 antibodies and methods for cancer treatment
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
SG10202110594UA (en) Methods of treating tumor
IL256025A (en) Methods of diagnosing and treating cancer
IL255569A (en) Methods of treating cancer using anti-ox40 antibodies
IL253462B2 (en) Cancer treatment with monoclonal antibodies against a latency-related peptide
IL266990A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
IL262342A (en) Cancer treatment methods
IL277981A (en) Cancer treatment methods
ZA201802481B (en) Novel biomarkers and methods of treating cancer
IL323981A (en) Cancer treatment methods
SG11202010793UA (en) Methods of treating cancer
ZA201908539B (en) Method of treatment of cancer
IL272810A (en) Methods for diagnosing and treating lung cancer
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
ZA202002144B (en) Antibodies and methods of use
SG11202005163PA (en) Methods of treating cancer
IL269123A (en) Methods of treating cancer
GB201609402D0 (en) Materials and methods for treating cancer
HK40053388B (en) Claudin6 antibodies and methods of treating cancer
SG11202108140SA (en) Anti-bag2 antibody and methods of treating cancer
HK40016654A (en) Methods of treating cancer with anti-tim-3 antibodies